| Protagonist Therapeutics is a clinical-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop peptide-based drugs. Co.'s clinical asset, PTG-300, is an injectable hepcidin mimetic in development for the potential treatment of iron overload and other blood disorders. Co. is developing PTG-300 for the treatment of ineffective erythropoiesis, chronic anemia and iron overload, with an initial focus on beta-thalassemia non-transfusion dependent and transfusion dependent patients. Co.'s other clinical assets, PTG-200 and PN-943, are orally delivered drugs in development for inflammatory bowel disease. We show 19 historical shares outstanding datapoints in our PTGX shares outstanding history coverage, used to compute PTGX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PTGX market cap history over the course of time is important for investors
interested in comparing PTGX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PTGX versus a peer is one thing; comparing
PTGX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PTGX can fluctuate over the course of history.
With this page we aim to empower investors researching PTGX by allowing them to research the PTGX market cap history.